|
gptkbp:instanceOf
|
gptkb:biotechnology
|
|
gptkbp:abbreviation
|
gptkb:Roche
|
|
gptkbp:focus
|
immunology
infectious diseases
neuroscience
oncology
ophthalmology
diagnostics
|
|
gptkbp:foundedBy
|
gptkb:Fritz_Hoffmann-La_Roche
|
|
gptkbp:foundedYear
|
1896
|
|
gptkbp:headquartersLocation
|
gptkb:Switzerland
Basel
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
F. Hoffmann-La Roche
|
|
gptkbp:industry
|
gptkb:biotechnology
pharmaceuticals
|
|
gptkbp:ISIN
|
CH0012032048
|
|
gptkbp:keyPerson
|
gptkb:Severin_Schwan
gptkb:Christoph_Franz
|
|
gptkbp:legalForm
|
gptkb:company
|
|
gptkbp:listedOn
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:logo
|
Roche_Logo.svg
|
|
gptkbp:marketCap
|
over CHF 200 billion (2023)
|
|
gptkbp:memberOf
|
gptkb:International_Federation_of_Pharmaceutical_Manufacturers_&_Associations
gptkb:European_Federation_of_Pharmaceutical_Industries_and_Associations
|
|
gptkbp:nativeName
|
gptkb:F._Hoffmann-La_Roche_AG
|
|
gptkbp:notableAcquisition
|
gptkb:Genentech
gptkb:Spark_Therapeutics
gptkb:Chugai_Pharmaceutical
gptkb:Flatiron_Health
|
|
gptkbp:notableEvent
|
Acquisition of Genentech in 2009
Acquisition of Chugai Pharmaceutical in 2002
Acquisition of Spark Therapeutics in 2019
|
|
gptkbp:notableProduct
|
gptkb:Avastin
gptkb:Herceptin
gptkb:MabThera
gptkb:Rituxan
gptkb:Rocephin
gptkb:Tamiflu
gptkb:Valium
gptkb:Xenical
|
|
gptkbp:numberOfEmployees
|
over 100,000 (2022)
|
|
gptkbp:parentCompany
|
gptkb:Roche_Holding_AG
|
|
gptkbp:rank
|
gptkb:Forbes_Global_2000
gptkb:Fortune_Global_500
|
|
gptkbp:revenue
|
CHF 63.3 billion (2022)
|
|
gptkbp:stockExchange
|
gptkb:SIX_Swiss_Exchange
|
|
gptkbp:stockSymbol
|
gptkb:ROG
|
|
gptkbp:subsidiary
|
gptkb:Genentech
gptkb:Chugai_Pharmaceutical
|
|
gptkbp:website
|
https://www.roche.com/
|
|
gptkbp:bfsParent
|
gptkb:Roche_family
gptkb:midazolam
|
|
gptkbp:bfsLayer
|
6
|